financetom
Business
financetom
/
Business
/
Marriott Vacations Q3 contract sales decline
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Marriott Vacations Q3 contract sales decline
Nov 5, 2025 1:43 PM

Overview

* Marriott Vacations ( VAC ) Q3 adjusted EPS beats analyst expectations

* Adjusted EBITDA for Q3 misses analyst estimates

* Contract sales declined 4% yr/yr due to lower tours and VPG declines

Outlook

* Company updates full-year 2025 contract sales guidance to $1.760 bln-$1.780 bln

* Company expects $150 mln-$200 mln Adjusted EBITDA benefit from modernization by 2026

* Company revises full-year adjusted EBITDA guidance to $740 mln-$755 mln

Result Drivers

* CONTRACT SALES DECLINE - Contract sales fell 4% due to a 1% decline in tours and a 5% decline in VPG

* STRATEGIC INITIATIVES - Co is realigning sales incentives and curbing third-party rentals to boost owner arrivals and satisfaction

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $1.69 $1.62 (9

Adjusted Analysts

EPS )

Q3 EPS -$0.07

Q3 Net -$2 mln

Income

Q3 Miss $170 mln $185.25

Adjusted mln (9

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and 2 "sell" or "strong sell"

* The average consensus recommendation for the hotels, motels & cruise lines peer group is "buy"

* Wall Street's median 12-month price target for Marriott Vacations Worldwide Corp ( VAC ) is $90.00, about 26.3% above its November 4 closing price of $66.32

* The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Kymera Therapeutics Q3 revenue misses analyst expectations, net loss widens
Kymera Therapeutics Q3 revenue misses analyst expectations, net loss widens
Nov 4, 2025
Overview * Kymera Q3 revenue missed analyst expectations * Net loss for Q3 was $82.2 mln, reflecting increased R&D expenses * Company remains well-capitalized with $979 mln cash, runway into 2H 2028 Outlook * Kymera expects KT-621 Phase 1b trial data in December 2025 * Company plans to initiate KT-621 Phase 2b asthma trial in 1Q26 * Kymera anticipates KT-579...
UL Solutions Q3 revenue beats; announces restructuring initiative
UL Solutions Q3 revenue beats; announces restructuring initiative
Nov 4, 2025
Overview * UL Solutions ( ULS ) Q3 revenue grows 7.1% to $783 mln, beating analyst expectations * Adjusted EBITDA of $217 mln beats estimates, reflecting strong operational performance * Company announces restructuring initiative to reduce expenses and improve efficiency Outlook * UL Solutions ( ULS ) expects 2025 organic revenue growth of 5.5% to 6% * Company anticipates 2025...
Norway poised to pause wealth fund's ethical divestments
Norway poised to pause wealth fund's ethical divestments
Nov 4, 2025
* Parliament debates pausing ethical divestments amid scrutiny * Finance Minister Stoltenberg cites need to protect fund's value * Government worried about Trump, says Socialist Left lawmaker By Gwladys Fouche OSLO, Nov 4 (Reuters) - Norway's parliament debated on Tuesday whether to pause ethical divestments by its $2.1 trillion sovereign wealth fund, the world's largest, while it updates the fund's...
SunCoke Q3 net income beats estimates
SunCoke Q3 net income beats estimates
Nov 4, 2025
Overview * SunCoke Q3 net income and adjusted EBITDA beat analyst expectations despite yr/yr decline * Company completed acquisition of Phoenix Global, contributing positively to Q3 results * Updated 2025 guidance reflects Phoenix Global integration and coke sales deferral due to breach Outlook * SunCoke updates full-year 2025 Consolidated Adjusted EBITDA to $220 mln - $225 mln * Company expects...
Copyright 2023-2026 - www.financetom.com All Rights Reserved